Suppr超能文献

药物重用于视网膜母细胞瘤:最新进展。

Drug Repurposing for Retinoblastoma: Recent Advances.

机构信息

CSIR-Centre for Cellular and Molecular Biology, Uppal Road, Habsiguda, Hyderabad 500 007, India.

Academy of Scientific and Innovative Research (AcSIR), Ghaziabad- 201002, India.

出版信息

Curr Top Med Chem. 2019;19(17):1535-1544. doi: 10.2174/1568026619666190119152706.

Abstract

Retinoblastoma is the intraocular malignancy that occurs during early childhood. The current standard of care includes chemotherapy followed by focal consolidative therapies, and enucleation. Unfortunately, these are associated with many side and late effects. New drugs and/or drug combinations need to be developed for safe and effective treatment. This compelling need stimulated efforts to explore drug repurposing for retinoblastoma. While conventional drug development is a lengthy and expensive process, drug repurposing is a faster, alternate approach, where an existing drug, not meant for treating cancer, can be repurposed to treat retinoblastoma. The present article reviews various attempts to test drugs approved for different purposes such as calcium channels blockers, non-steroidal antiinflammatory drugs, cardenolides, antidiabetic, antibiotics and antimalarial for treating retinoblastoma. It also discusses other promising candidates that could be explored for repurposing for retinoblastoma.

摘要

视网膜母细胞瘤是儿童期发生的眼内恶性肿瘤。目前的治疗标准包括化疗后进行局部巩固治疗和眼球摘除术。然而,这些治疗方法都伴随着许多副作用和晚期效应。因此,需要开发新的药物和/或药物组合,以实现安全有效的治疗。这种迫切的需求促使人们努力探索将药物重新用于治疗视网膜母细胞瘤。虽然传统的药物开发是一个漫长而昂贵的过程,但药物再利用是一种更快、替代的方法,即可以将原本不是用于治疗癌症的现有药物重新用于治疗视网膜母细胞瘤。本文综述了各种尝试,以测试已批准用于不同用途的药物,如钙通道阻滞剂、非甾体类抗炎药、强心苷、抗糖尿病药、抗生素和抗疟药,以治疗视网膜母细胞瘤。还讨论了其他可能被探索用于治疗视网膜母细胞瘤的有前途的候选药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验